BridgeMD
New treatment option for Oral Lichen Planus
Official title Photobiomodulation, Photodynamic Therapy, and Clobetasol in the Treatment of Oral Lichen Planus.
ClinicalTrials.gov ID: NCT07278999
What this study is testing
What is Clobetasol propionate 0.05 percent topical application?
Clobetasol propionate 0.05 percent topical application is an investigational medicine, given as an once-weekly pill taken by mouth, being studied as a potential treatment for oral lichen planus.
Also referred to as Topical corticosteroid.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to compare three treatment approaches for the erosive form of oral lichen planus, a chronic inflammatory condition that often causes pain, impaired oral function, and frequent relapses. Sixty adults with a confirmed diagnosis will be randomly assigned to photobiomodulation, Photodynamic Therapy, or topical clobetasol, which serves as the current standard of care.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 20 to 70
You may be able to join if
- Be between 20 and 70 years old.
- Have histologically confirmed erosive or ulcerative oral lichen planus based on a biopsy.
- Have no active aerobic bacterial infection or oral fungal infection.
- Have had no treatment for OLP within the past 3 months.
- Provide written informed consent.
You likely can't join if
- Systemic diseases or conditions such as uncontrolled diabetes (random glucose ≥200 mg/dl), cardiovascular failure, or a pacemaker.
- Autoimmune/connective tissue diseases such as lupus with positive ANA testing.
- Current or past cancer, graft-versus-host disease, or hematologic disorders (anemia, leukemia, lymphoma, bleeding disorders, hemophilia, von...
- Enzymatic or metabolic disorders such as G6PD deficiency (favism) or porphyria.
- Viral hepatitis A, B, or C.
- Recent vaccinations (within the past 6 months).
See the full eligibility criteria
- Be between 20 and 70 years old.
- Have histologically confirmed erosive or ulcerative oral lichen planus based on a biopsy.
- Have no active aerobic bacterial infection or oral fungal infection.
- Have had no treatment for OLP within the past 3 months.
- Provide written informed consent.
- Systemic diseases or conditions such as uncontrolled diabetes (random glucose ≥200 mg/dl), cardiovascular failure, or a pacemaker.
- Autoimmune/connective tissue diseases such as lupus with positive ANA testing.
- Current or past cancer, graft-versus-host disease, or hematologic disorders (anemia, leukemia, lymphoma, bleeding disorders, hemophilia, von Willebrand disease).
- Enzymatic or metabolic disorders such as G6PD deficiency (favism) or porphyria.
- Viral hepatitis A, B, or C.
- Recent vaccinations (within the past 6 months).
- Use of medications known to trigger lichenoid reactions, including:
- Antihypertensives (beta-blockers, diuretics, ACE inhibitors, centrally acting agents).
- Oral antidiabetics (sulfonylureas).
- Metal-containing compounds (lithium, gold, arsenic, mercury).
- NSAIDs (e.g., ibuprofen).
- Antibiotics/chemotherapeutics (tetracyclines, sulfonamides).
- Pregnancy or breastfeeding (including up to 6 months post-lactation).
- Photosensitivity to UV light.
- Smoking more than 5 cigarettes per day.
- Lesions located adjacent to amalgam fillings or metal prosthetic restorations.
- Any degree of dysplasia on histopathology.
- Treatment for OLP within the last 3 months.
- Active oral fungal or bacterial infection at screening.
- Lack of consent to participate.
The study team makes the final eligibility decision.
Where it's taking place
- Zabrze, Silesian Voivodeship, Poland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 20 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Zabrze, Silesian Voivodeship, Poland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.